Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.
Replimune finally got government approval to sell a new skin cancer medicine after facing rejections. This shows the company can finish what it started, even when things get messy—which is worth watching to see if their medicine actually helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.